Have you previously been screened for lung cancer? Or are you currently scheduled for a lung cancer screening? We are looking for Black/African American men and women between the ages of 50-80 to participate in a study about lung cancer. Compensation is provided.

Do you have Acute Myeloid Leukemia (AML) and want to try a new study drug that might help treat your cancer?

Have you been diagnosed with GCB Subtype of Diffuse LargeB-cell Lymphoma (DLBCL)? If so, you may be able to take part in a research study looking at Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL

The purpose of this study is to see at what doses of etentamig combined with Iberdomide is better tolerated and safe for patients with relapsed/refractory multiple myeloma.

We want to see if people with breast cancer that has spread to other parts of the body can join and benefit from a 16-week exercise program at Get Real and Heel.

The purpose of this study is to test if BGB-16673 and pirtobrutinib are safe and test how well BGB-16673 compares to pirtobrutinib in participants with previously treated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

If you have Leukemia and are looking for an alternative treatment, you may be eligible to participate in a research study testing a new drug called AUTX-007.

Are you 18 years of age and younger than 75 years old? Do you or do you know someone with Peripheral T-cell Lymphoma? Would you be interested in using your own stem cells versus only using chemotherapy infusions? If you have large cell lymphoma (ALCL) ALK-negative, this study may interest you.

To evaluate the anti-tumor activity of carboplatin + MIRV in newly diagnosed subjects with advanced-stage (≥ 75%, ≥ 2+) serous EOC as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 imaging response.

In this study, we want to look at how the drug tirzepatide works in patients with endometrial cancer compared to the standard of care treatment. We will be looking at its effect on the progression of the tumor.